Urology · 2025
Histologic Concordance Between Post-chemotherapy RPLND and Orchiectomy When Performed Simultaneously: Insights Into the Blood-testis Barrier.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thakker Parth U, Zeng Jiping, Drake Connor, Brown James, Masterson Timothy A, Cary Kelly
Аннотация
OBJECTIVE: To compare the histology of patients undergoing concomitant orchiectomy and PC-RPLND to understand the interaction of chemotherapeutics with the blood-testis barrier.
METHODS: We identified patients undergoing orchiectomy at the time of PC-RPLND using an institutional database. Concordance between the PC-RPLND and orchiectomy histology was assessed. Univariable logistic regression for age, mass size, pre-chemotherapy RP biopsy, and testis mass size, and receipt of bleomycin chemotherapy on detecting teratoma in the orchiectomy specimen was performed.
RESULTS: Fifty-seven patients undergoing orchiectomy at the time of PC-RPLND were identified. Concordance between PC-RPLND and orchiectomy pathology was observed in 29 (50.9%) patients. Univariable analysis demonstrated that pre-operative RP mass size (OR 0.93, 95% CI 0.80-1.07), receipt of bleomycin (OR 1.56, 95% CI 0.42-5.8), pre-chemotherapy testis mass size (OR 1.11, 95% CI 0.83-1.47), age at surgery (OR 0.99, 95% CI 0.70-1.39), pre-chemotherapy RP histology (OR 2.4, 95% CI 0.48-11.8), nor time from chemotherapy to surgery (OR 1.0, 95% CI 0.72-1.39) were associated with finding teratoma on orchiectomy.
CONCLUSION: With 60% of testis masses revealing necrosis, chemotherapy appears to penetrate the blood-testis barrier, however, with a 1.5% incidence of ITGCN, its ability to do so is not predictable. Since identifying teratoma in the testis remains a challenge, delayed orchiectomy in patients undergoing upfront chemotherapy should remain a standard of care.
METHODS: We identified patients undergoing orchiectomy at the time of PC-RPLND using an institutional database. Concordance between the PC-RPLND and orchiectomy histology was assessed. Univariable logistic regression for age, mass size, pre-chemotherapy RP biopsy, and testis mass size, and receipt of bleomycin chemotherapy on detecting teratoma in the orchiectomy specimen was performed.
RESULTS: Fifty-seven patients undergoing orchiectomy at the time of PC-RPLND were identified. Concordance between PC-RPLND and orchiectomy pathology was observed in 29 (50.9%) patients. Univariable analysis demonstrated that pre-operative RP mass size (OR 0.93, 95% CI 0.80-1.07), receipt of bleomycin (OR 1.56, 95% CI 0.42-5.8), pre-chemotherapy testis mass size (OR 1.11, 95% CI 0.83-1.47), age at surgery (OR 0.99, 95% CI 0.70-1.39), pre-chemotherapy RP histology (OR 2.4, 95% CI 0.48-11.8), nor time from chemotherapy to surgery (OR 1.0, 95% CI 0.72-1.39) were associated with finding teratoma on orchiectomy.
CONCLUSION: With 60% of testis masses revealing necrosis, chemotherapy appears to penetrate the blood-testis barrier, however, with a 1.5% incidence of ITGCN, its ability to do so is not predictable. Since identifying teratoma in the testis remains a challenge, delayed orchiectomy in patients undergoing upfront chemotherapy should remain a standard of care.